125 related articles for article (PubMed ID: 10373682)
61. Cancer genetics in the new era of molecular biology.
Lynch HT; Fusaro RM; Lynch JF
Ann N Y Acad Sci; 1997 Dec; 833():1-28. PubMed ID: 9616736
[TBL] [Abstract][Full Text] [Related]
62. Altered expression of mismatch repair proteins associated with acquisition of microsatellite instability in a clonal model of human T lymphocyte aging.
Neri S; Pawelec G; Facchini A; Ferrari C; Mariani E
Rejuvenation Res; 2008 Jun; 11(3):565-72. PubMed ID: 18484899
[TBL] [Abstract][Full Text] [Related]
63. Expression of five selected human mismatch repair genes simultaneously detected in normal and cancer cell lines by a nonradioactive multiplex reverse transcription-polymerase chain reaction.
Wei Q; Guan Y; Cheng L; Radinsky R; Bar-Eli M; Tsan R; Li L; Legerski RJ
Pathobiology; 1997; 65(6):293-300. PubMed ID: 9491849
[TBL] [Abstract][Full Text] [Related]
64. The role of MLH1, MSH2 and MSH6 in the development of multiple colorectal cancers.
Lawes DA; Pearson T; Sengupta S; Boulos PB
Br J Cancer; 2005 Aug; 93(4):472-7. PubMed ID: 16106253
[TBL] [Abstract][Full Text] [Related]
65. [Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers].
Hu XR; Xu C; Kang Y; Wang T; Zhang Y; Yang XH
Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):827-833. PubMed ID: 30423605
[No Abstract] [Full Text] [Related]
66. Characterization of the interactome of the human MutL homologues MLH1, PMS1, and PMS2.
Cannavo E; Gerrits B; Marra G; Schlapbach R; Jiricny J
J Biol Chem; 2007 Feb; 282(5):2976-86. PubMed ID: 17148452
[TBL] [Abstract][Full Text] [Related]
67. Different mutator phenotypes in Mlh1- versus Pms2-deficient mice.
Yao X; Buermeyer AB; Narayanan L; Tran D; Baker SM; Prolla TA; Glazer PM; Liskay RM; Arnheim N
Proc Natl Acad Sci U S A; 1999 Jun; 96(12):6850-5. PubMed ID: 10359802
[TBL] [Abstract][Full Text] [Related]
68. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer.
Southey MC; Jenkins MA; Mead L; Whitty J; Trivett M; Tesoriero AA; Smith LD; Jennings K; Grubb G; Royce SG; Walsh MD; Barker MA; Young JP; Jass JR; St John DJ; Macrae FA; Giles GG; Hopper JL
J Clin Oncol; 2005 Sep; 23(27):6524-32. PubMed ID: 16116158
[TBL] [Abstract][Full Text] [Related]
69. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma.
Hall G; Clarkson A; Shi A; Langford E; Leung H; Eckstein RP; Gill AJ
Pathology; 2010; 42(5):409-13. PubMed ID: 20632815
[TBL] [Abstract][Full Text] [Related]
70. Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents.
Francia G; Green SK; Bocci G; Man S; Emmenegger U; Ebos JM; Weinerman A; Shaked Y; Kerbel RS
Mol Cancer Ther; 2005 Oct; 4(10):1484-94. PubMed ID: 16227397
[TBL] [Abstract][Full Text] [Related]
71. Immunohistochemical survey of mismatch repair protein expression in uterine sarcomas and carcinosarcomas.
Hoang LN; Ali RH; Lau S; Gilks CB; Lee CH
Int J Gynecol Pathol; 2014 Sep; 33(5):483-91. PubMed ID: 25083964
[TBL] [Abstract][Full Text] [Related]
72. Mutations in mismatch repair genes are involved in the neoplastic transformation of human breast epithelial cells.
Balogh GA; Russo IH; Russo J
Int J Oncol; 2003 Aug; 23(2):411-9. PubMed ID: 12851690
[TBL] [Abstract][Full Text] [Related]
73. Loss of expression of DNA mismatch repair proteins is rare in pancreatic and small intestinal neuroendocrine tumors.
Arnason T; Sapp HL; Rayson D; Barnes PJ; Drewniak M; Nassar BA; Huang WY
Arch Pathol Lab Med; 2011 Dec; 135(12):1539-44. PubMed ID: 22129180
[TBL] [Abstract][Full Text] [Related]
74. Elevated levels of the mismatch repair protein PMS2 are associated with prostate cancer.
Norris AM; Woodruff RD; D'Agostino RB; Clodfelter JE; Scarpinato KD
Prostate; 2007 Feb; 67(2):214-25. PubMed ID: 17044039
[TBL] [Abstract][Full Text] [Related]
75. Elevated mutant frequencies and increased C : G-->T : A transitions in Mlh1-/- versus Pms2-/- murine small intestinal epithelial cells.
Baross-Francis A; Makhani N; Liskay RM; Jirik FR
Oncogene; 2001 Feb; 20(5):619-25. PubMed ID: 11313994
[TBL] [Abstract][Full Text] [Related]
76. Signaling mismatch repair in cancer.
Fishel R
Nat Med; 1999 Nov; 5(11):1239-41. PubMed ID: 10545986
[TBL] [Abstract][Full Text] [Related]
77. Defective mismatch repair in the pathogenesis of low-grade appendiceal mucinous neoplasms and adenocarcinomas.
Misdraji J; Burgart LJ; Lauwers GY
Mod Pathol; 2004 Dec; 17(12):1447-54. PubMed ID: 15354187
[TBL] [Abstract][Full Text] [Related]
78. Reduced isotype switching in splenic B cells from mice deficient in mismatch repair enzymes.
Schrader CE; Edelmann W; Kucherlapati R; Stavnezer J
J Exp Med; 1999 Aug; 190(3):323-30. PubMed ID: 10430621
[TBL] [Abstract][Full Text] [Related]
79. Identification of hMutLbeta, a heterodimer of hMLH1 and hPMS1.
Räschle M; Marra G; Nyström-Lahti M; Schär P; Jiricny J
J Biol Chem; 1999 Nov; 274(45):32368-75. PubMed ID: 10542278
[TBL] [Abstract][Full Text] [Related]
80. Resistance to topoisomerase poisons due to loss of DNA mismatch repair.
Fedier A; Schwarz VA; Walt H; Carpini RD; Haller U; Fink D
Int J Cancer; 2001 Aug; 93(4):571-6. PubMed ID: 11477562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
